The development of acquired inhibitors of coagulation factor XI (FXI) in patients without congenital deficiency is an extremely rare phenomenon and has been reported mostly in patients with autoimmune diseases or in association with malignancies [2, 3]. Here, F11 is linked to autoimmune disease.